What loading and maintenance gentamicin dose should be given to a 42‑year‑old, 98‑kg male with infective endocarditis and an estimated creatinine clearance of ~106 mL/min, and how should the dose be adjusted based on a trough of 2 mg/L and peak of 6 mg/L measured before the fourth dose?

Gentamicin Dosing for Enterococcus faecalis Infective Endocarditis

For this 42-year-old, 98 kg male with E. faecalis endocarditis, initiate gentamicin 294 mg (3 mg/kg) IV once daily for synergy with ceftriaxone, with a planned 2-week duration. 1

Initial Dosing Calculations

Patient Parameters

• Actual body weight: 98 kg
• Height: 5'7" (170 cm)
• SCr: 111.2 μmol/L = 1.26 mg/dL
• Estimated CrCl (Cockcroft-Gault):
  • CrCl = [(140 - 42) × 98] / (72 × 1.26) = 106 mL/min
• Renal function: Normal

Loading and Maintenance Dose

For endocarditis synergy dosing, there is NO separate loading dose. The maintenance dose IS the therapeutic dose 1, 2.

Initial dose: 3 mg/kg × 98 kg = 294 mg IV once daily

This aligns with AHA guidelines recommending 3 mg/kg/day as a single daily dose for enterococcal endocarditis 1. The FDA label confirms this dosing for serious infections in patients with normal renal function 2.

Rationale for Once-Daily Dosing

Once-daily gentamicin dosing (versus divided doses) for endocarditis synergy is supported by:

• Significantly lower nephrotoxicity: 13% vs 52.5% AKI incidence 3
• Fewer dose adjustments required: 21.7% vs 76.2% 3
• Shorter hospital stays 3
• Non-inferior efficacy for infection control 4

The AHA guidelines explicitly state that once-daily dosing is preferred, though divided dosing (3 equally divided doses) is listed as a second option 1.

Initial Communication to Team

GENTAMICIN DOSING RECOMMENDATION

• Dose: 294 mg (3 mg/kg) IV once daily
• Duration: 2 weeks (in combination with ceftriaxone)
• Infusion: Over 30-60 minutes
• Monitoring:
  • Draw trough level immediately before 4th dose (72 hours after initiation)
  • Target trough: <2 mg/L 2
  • Peak monitoring not routinely needed for once-daily synergy dosing
  • Monitor SCr every 2-3 days

Clinical Pearl: For E. faecalis endocarditis, gentamicin serves a synergistic role (not monotherapy), requiring only 2 weeks of treatment when combined with a cell-wall active agent 1, 5.

---

Dose Adjustment Based on Observed Levels

SOAP Note for Dose Adjustment

S (Subjective): Patient receiving gentamicin 294 mg IV daily for E. faecalis endocarditis synergy with ceftriaxone.

O (Objective):

• Trough (pre-4th dose): 2 mg/L
• Peak (1 hour post-dose): 6 mg/L
• Current dose: 294 mg (3 mg/kg) once daily
• SCr: 111.2 μmol/L (stable)
• CrCl: ~106 mL/min

A (Assessment):

CRITICAL ISSUE: These levels indicate SUBTHERAPEUTIC dosing and incorrect sampling.

1. Trough of 2 mg/L is at the upper acceptable limit (target <2 mg/L) 2, but acceptable for once-daily dosing
2. Peak of 6 mg/L is INADEQUATELY LOW for once-daily dosing
   • Expected peak for 3 mg/kg dosing: 15-20 mg/L 6
   • Therapeutic target for aminoglycoside efficacy: Peak >16 mg/L for serious infections 6
   • Current peak suggests either:
     • Sampling error (drawn too late after infusion)
     • Increased volume of distribution
     • Dosing calculation error

Pharmacokinetic Calculations

Using one-compartment model (Sawchuk-Zaske method):

Step 1: Calculate elimination rate constant (Ke)

• Ke = ln(Cpeak/Ctrough) / τ
• Ke = ln(6/2) / 24 = 0.0458 hr⁻¹

Step 2: Calculate half-life

• t½ = 0.693/Ke = 0.693/0.0458 = 15.1 hours

Step 3: Calculate volume of distribution (Vd)

• Vd = Dose / (Cpeak - Ctrough)
• Vd = 294 mg / (6 - 2) mg/L = 73.5 L
• Vd/kg = 73.5/98 = 0.75 L/kg (markedly elevated; expected 0.25-0.3 L/kg)

This elevated Vd explains the low peak and suggests the patient requires a HIGHER dose to achieve therapeutic levels.

Step 4: Calculate revised dose for target peak of 18 mg/L

• Target Cpeak = 18 mg/L (mid-range for efficacy)
• Target Ctrough = 1 mg/L (safer margin)
• Required dose = Vd × (Cpeak - Ctrough)
• Required dose = 73.5 L × (18 - 1) mg/L = 1,250 mg ≈ 1,200 mg

Alternative calculation using mg/kg:

• To achieve peak 16-20 mg/L with elevated Vd: 12 mg/kg
• 12 mg/kg × 98 kg = 1,176 mg ≈ 1,200 mg

However, this dose exceeds typical endocarditis synergy dosing and raises toxicity concerns.

P (Plan):

Recommended Actions:

1. FIRST: Verify the peak level timing and redraw

   • Peak should be drawn 30-60 minutes post-infusion completion 2
   • If drawn at 1 hour post-START of infusion (not completion), this explains the low value
   • Redraw peak 30 minutes after next dose completion

2. IF peak truly 6 mg/L at correct timing:

   • Increase dose to 490 mg (5 mg/kg) IV once daily
   • This is within FDA-approved range for life-threatening infections (up to 5 mg/kg/day) 2
   • Recheck levels after 3rd dose of new regimen:
     • Peak: 30-60 min post-infusion (target 16-20 mg/L)
     • Trough: immediately before next dose (target <2 mg/L)

3. Continue monitoring:

   • SCr every 2-3 days
   • Discontinue gentamicin after 2 weeks total (per guidelines) 1
   • Continue ceftriaxone for full 6-week course

4. Consider alternative regimen:

   • Given the complexity and potential for toxicity with high-dose gentamicin, consider switching to ampicillin 2g IV q4h + ceftriaxone 2g IV daily (gentamicin-free regimen) 7, 8
   • This combination shows non-inferior efficacy with significantly less nephrotoxicity for E. faecalis endocarditis 7

Critical Pitfalls to Avoid:

• Do NOT use traditional divided-dose gentamicin (1 mg/kg q8h) for endocarditis—this increases nephrotoxicity without improving efficacy 3
• Do NOT continue gentamicin beyond 2 weeks—no additional benefit and increased toxicity risk 1
• Do NOT target high troughs—troughs >2 mg/L significantly increase nephrotoxicity risk 2, 9
• Verify sampling times—incorrect timing is the most common cause of unexpected levels

Given this patient's elevated Vd and the marginal benefit of aminoglycosides in E. faecalis endocarditis, strongly consider transitioning to the ampicillin-ceftriaxone regimen, which avoids aminoglycoside toxicity entirely while maintaining equivalent efficacy 7, 8.